Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-(HE)3-ZHER3-NODAGA
- Development stage
- Preclinical
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]Ga-(HE)3-ZHER3-NODAGA is a gallium-68 labeled affibody-based radiopharmaceutical designed for positron emission tomography (PET) imaging of human epidermal growth factor receptor 3 (HER3, ErbB3) expression in tumors. It consists of the anti-HER3 affibody molecule ZHER3 (specifically Z08698) modified with a hydrophilic N-terminal histidine-glutamate tag (HE)3 to reduce hepatic uptake and improve biodistribution, conjugated to the chelator NODAGA, and radiolabeled with the positron emitter gallium-68. Preclinical studies have demonstrated that [68Ga]Ga-(HE)3-ZHER3-NODAGA provides high-contrast PET imaging of HER3 expression with rapid blood clearance and high tumor-to-non-tumor ratios, making it a promising candidate for patient stratification in HER3-targeted cancer therapies.
- Other names
- (HE)3-Z08698-NODAGA(HE)3-ZHER3-NODAGAHEHEHE-Z08698-NODAGAHEHEHE-Z-08698-NODAGAHEHEHE-Z 08698-NODAGA
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on [68Ga]Ga-(HE)3-ZHER3-NODAGA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-(HE)3-ZHER3-NODAGA.